Multicenter phase 3 clinical study of early surgical treatment of recurrent asymptomatic glioblastomas

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000037350

Enrollment

Unknown

Registered

2020-08-28

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioma

Interventions

experimental group:Temozolomide + early surgery

control group:Temozolomide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Glioblastoma or gliosarcoma confirmed by histology; 2. Experienced radiologists highly suspected of early tumor progression or recurrence; 3. No neurological symptoms; 4. Patients aged 18 or above; 5. ECOG 0-2; 6. Patients who sign informed consent.

Exclusion criteria

Exclusion criteria: After simultaneous radiotherapy and chemotherapy, the recurrence or progress of primary glioblastomas has obvious neurological symptoms.

Design outcomes

Primary

Measure	Time frame
Median survival time;	—

Secondary

Measure	Time frame
Progression free survival time;	—

Countries

China

Contacts

Public ContactZhiyong Qin

Huashan Hospital Affiliated to Fudan University

wisdomqin@vip.163.com+86 13701601840

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026